112 related articles for article (PubMed ID: 23886435)
1. Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus.
Natesan SK; Lamichchane AK; Swaminathan S; Wu W
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):458-63. PubMed ID: 23886435
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
[TBL] [Abstract][Full Text] [Related]
3. Magnitude of Voriconazole Resistance in Clinical and Environmental Isolates of Aspergillus flavus and Investigation into the Role of Multidrug Efflux Pumps.
Paul RA; Rudramurthy SM; Dhaliwal M; Singh P; Ghosh AK; Kaur H; Varma S; Agarwal R; Chakrabarti A
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126956
[TBL] [Abstract][Full Text] [Related]
4. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis.
Liu W; Sun Y; Chen W; Liu W; Wan Z; Bu D; Li R
Antimicrob Agents Chemother; 2012 May; 56(5):2598-603. PubMed ID: 22314539
[TBL] [Abstract][Full Text] [Related]
5. Contributions of
Ukai Y; Kuroiwa M; Kurihara N; Naruse H; Homma T; Maki H; Naito A
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126960
[No Abstract] [Full Text] [Related]
6. Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India.
Sharma C; Kumar R; Kumar N; Masih A; Gupta D; Chowdhary A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311090
[TBL] [Abstract][Full Text] [Related]
7. In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus.
Krishnan Natesan S; Wu W; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):272-7. PubMed ID: 22897872
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole resistance genes in Aspergillus flavus clinical isolates.
Zaini F; Lotfali E; Fattahi A; Siddig E; Farahyar S; Kouhsari E; Saffari M
J Mycol Med; 2020 Jun; 30(2):100953. PubMed ID: 32362445
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite Typing and Resistance Mechanism Analysis of Voriconazole-Resistant
Choi MJ; Won EJ; Joo MY; Park YJ; Kim SH; Shin MG; Shin JH
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30397064
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.
Rudramurthy SM; Seyedmousavi S; Dhaliwal M; Chakrabarti A; Meis JF; Mouton JW
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821453
[TBL] [Abstract][Full Text] [Related]
11. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity.
Rajendran R; Mowat E; McCulloch E; Lappin DF; Jones B; Lang S; Majithiya JB; Warn P; Williams C; Ramage G
Antimicrob Agents Chemother; 2011 May; 55(5):2092-7. PubMed ID: 21321135
[TBL] [Abstract][Full Text] [Related]
12. Increased expression and hotspot mutations of the multidrug efflux transporter, CDR1 in azole-resistant Candida albicans isolates from vaginitis patients.
Looi CY; D' Silva EC; Seow HF; Rosli R; Ng KP; Chong PP
FEMS Microbiol Lett; 2005 Aug; 249(2):283-9. PubMed ID: 16006060
[TBL] [Abstract][Full Text] [Related]
13. Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis?
Calvo E; Pastor FJ; Sutton DA; Fothergill AW; Rinaldi MG; Salas V; Guarro J
Diagn Microbiol Infect Dis; 2012 Oct; 74(2):158-65. PubMed ID: 22858549
[TBL] [Abstract][Full Text] [Related]
14. Azole resistance mechanisms in Aspergillus: update and recent advances.
Pérez-Cantero A; López-Fernández L; Guarro J; Capilla J
Int J Antimicrob Agents; 2020 Jan; 55(1):105807. PubMed ID: 31542320
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
17. Aneuploidy Formation in the Filamentous Fungus Aspergillus flavus in Response to Azole Stress.
Barda O; Sadhasivam S; Gong D; Doron-Faigenboim A; Zakin V; Drott MT; Sionov E
Microbiol Spectr; 2023 Aug; 11(4):e0433922. PubMed ID: 37358460
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Rudramurthy SM; Chakrabarti A; Geertsen E; Mouton JW; Meis JF
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):370-7. PubMed ID: 21937186
[TBL] [Abstract][Full Text] [Related]
19. Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.
Pina-Vaz C; Rodrigues AG; Costa-de-Oliveira S; Ricardo E; Mårdh PA
J Antimicrob Chemother; 2005 Oct; 56(4):678-85. PubMed ID: 16115827
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp.
Castro C; Serrano MC; Flores B; Espinel-Ingroff A; Martín-Mazuelos E
J Clin Microbiol; 2004 Sep; 42(9):4358-60. PubMed ID: 15365044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
